Feasibility trial reports deployment of new device for TAVI in aortic insufficiency
23 May 2013, Paris, France: A new investigational device - the Helio System (TF-FA) - being developed for use with the Sapien XT Transcatheter Heart Valve was successfully deployed in all four patients in a small, first-in-human feasibility study of its use in high-risk aortic insufficiency reported at EuroPCR 2013.
The HELIO dock system acts as an anchor to help stabilise the SAPIEN XT valve for patients with aortic insufficiency. The native leaflets in the heart are captured between the transcatheter heart valve and the dock. "This is an innovative, minimally invasive ...